Prostate_Cancer

Prostate Cancer Andy Fan Prostate cancer is one of the major causes of death in men of the Western world. There are over 317,100 newly diagnosed cases and around 41,500 prostate cancer related deaths reported in North America (Kondo, et al., 2000). Of the people diagnosed for prostate cancer, approximately 20% of them will eventually develop androgen-independent tumors for which there is no effective cure (Voeks, et al., 2002). As of now, treatment of non-organ confined prostatic carcinoma requires either surgical or pharmacological castration. While surgery and radiation therapy are also effective for treatment of localized tumors, there is no effective cure for advanced or metastatic tumors, tumors made up of cancerous cells which migrate from the original site to other sites in the body. Hormonal therapies and chemotherapy are also available but they are generally ineffective in dealing with the advanced stages of prostate cancer. (Kondo, et al., 2000). The aim of therapy is to prevent androgenic stimulation of the tumor. Efforts to remove the tumor and the surrounding tissue with androgen ablation are often combined with the blockade of the androgen receptor by various anti-androgens. Androgens are responsible for the regulation of growth and development of the prostate gland. The use of cells, cancer, prostate, et, al, tumors, tumor, psma, cell, voeks, treatment, gong, fludarabine, 2002, 2000, 1999, therapy, kondo, effective, using, phosphate, modified, lymphocytes, increase, genetically, gene, gdept, days, being, androgen, volume, therapies, target, oadv220, made, lipofectamine